Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients

Abstract

Four weeks of treatment with rosiglitazone significantly reduces vascular inflammation in nondiabetic patients, leading to a more stable type of arteriosclerotic lesion.